Human Tumor Necrosis Factor Receptor Type 1
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Purification : | Reducing and Non-Reducing SDS PAGE at >= 95% |
| Content : | Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 10 mM sodium phosphate, pH 7.5 Sterile water at 0.1 mg/mL |
| Storage condition : | Store at -20°C |
| AA sequence : | MDSVCPQGKY IHPQNNSICC TKCHKGTYLY NDCPGPGQDT DCRECESGSF TASENHLRHC LSCSKCRKEM GQVEISSCTV DRDTVCGCRKN QYRHYWSENL FQCFNCSLCL NGTVHLSCQE KQNTVCTCHA GFFLRENECV SCSNCKKSLE CTKLCLPQI EN |
Predicted MW:Â Monomer, 18.3 kDa (162 aa)
Tumor necrosis factor receptor type 1 (TNFR1) is expressed in most tissues and is activated by soluble and membrane-bound tumor necrosis factor alpha (TNFa). TNFR1 activates NF-kB and MAPK pathways to induce inflammation, promote apoptotic cell death, inhibit tumorigenesis, and inhibit viral replication.Â
Endotoxin: Less than 0.1 ng/µg (1 IEU/µg) as determined by LAL test.
Biological Activity was determined by Neutralization of human TNF alpha induced L929 cell cytolysis at <=100 ng/mL; >= 1.0 x 10^4 units/mg. Centrifuge vial before opening, Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws. Upon reconstitution, a small amount of visible precipitate can be expected. A 10% overfill has been added to the total material vialed to compensate for this loss.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
| Subcellular location: | Secreted |
| Post transnational modification: | The soluble form is produced from the membrane form by proteolytic processing. |
| BioGrid: | 112986. 162 interactions. |
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
